US-based alternative investment firm H.I.G. Capital (HIG) has announced the sale of Soleo Health to funds managed by Court Square Capital and WindRose Health Investors.

Soleo is a diversified omnichannel infusion platform providing complex speciality pharmacy services and infusion therapy administered at home or alternate care sites.

The company operates 26 pharmacies with national nursing coverage and pharmacy licensure in 50 states, along with 30 ambulatory infusion suites in the US.

Its team comprises highly experienced clinical pharmacists, registered nurses, reimbursement specialists, and patient care ambassadors.

Building on its pharmacy licensure and specialised nursing network, Soleo offers personalised healthcare to patients with complex, rare, and ultra-rare medical conditions.

Also, the firm is accredited by the URAC, ACHC, with Distinction in Rare Diseases and Orphan Drugs, the National Association of Boards of Pharmacy, and the Joint Commission.

Soleo president and CEO Drew Walk said: “H.I.G. has been an exceptional partner to Soleo and instrumental in helping us build the Company into the market leader we are today.

“H.I.G. supported several significant investments in talent and infrastructure, strengthening our ability to reach more patients and provide exceptional care across our network.”

HIG is an alternative investment firm with $67bn of capital under management, specialising in providing both debt and equity capital to middle-market companies.

The investment firm has offices in Atlanta, Boston, Chicago, Los Angeles, New York, and San Francisco in the US.

It also has international affiliate offices in Hamburg, London, Luxembourg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro, São Paulo, Dubai, and Hong Kong.

HIG said it has supported Soleo in building the speciality pharmacy and infusion business by enhancing its footprint with de novo pharmacy and infusion suite expansions.

It has introduced a differentiated therapy-specific clinical model, diversifying payor, site-of-care and therapy offerings, and making key executive hires.

H.I.G. managing director Scott Zhu said: “Drew and the Soleo management team have done an outstanding job transforming Soleo from a regional infusion player into a national speciality care provider, with a variety of compelling growth opportunities.

“Soleo is an exceptional infusion platform led by a best-in-class leadership team, and we look forward to watching the Company’s continued growth.”